Novo Nordisk (NVO) Stock: Is the 8% Drop an Overreaction or a Warning Sign?

TLDR

• NVO stock fell nearly 8% on Monday, its steepest single-day drop since February
• New CEO Mike Doustdar said Novo is open to M&A to fill pipeline gaps, particularly in cardiovascular disease
• Wegovy and Ozempic face patent expiries in the early 2030s and account for about 75% of total sales
• Novo targets 5+ new blockbuster drugs by 2030 and over $23 billion in new sales by 2035
• The company has repurchased DKK 9.63 billion in B shares as part of a DKK 15 billion buyback programme

---

Novo Nordisk stock dropped nearly 8% on Monday after its capital markets day failed to reassure investors about the company’s long-term pipeline. The stock was trading at $39.80, down $3.44, before edging slightly lower again on Tuesday.

Novo Nordisk A/S, NVO

The sell-off came after investors largely viewed Novo’s targets as already priced in rather than a positive surprise.

New CEO Mike Doustdar acknowledged the market reaction. Speaking on CNBC’s “Squawk Box Europe,” he said: “We talked about diversification of the company, but yet the reaction tells me that there’s still some work to do in convincing some of the investors.”

Doustdar also admitted the company had a credibility problem to fix. “What we have learned the last couple of years is overpromising and underdelivering loses trust very quickly,” he told Bloomberg TV.

The company has set a target of more than five new blockbuster drugs by 2030 and over $23 billion in new sales by 2035. Investors were not moved.

Patent Cliff Is the Core Concern

The central issue is the patent expiry clock. Ozempic and Wegovy, which together make up roughly three-quarters of Novo’s sales, face patent expiries in the United States and Europe in the early 2030s.

That leaves a narrow window to build out a pipeline that can replace that revenue. Doustdar said Novo is actively looking at acquisitions to fill gaps, particularly in areas adjacent to obesity like cardiovascular disease.

The push into cardiovascular came after Novo’s experimental drug ziltivekimab failed to reduce heart attack risk in a clinical trial earlier this year. Doustdar said the company is now weighing whether that gap can be filled through an external deal.

He noted there were fewer attractive acquisition targets in obesity itself, so the M&A focus is likely to shift to adjacent therapeutic areas.

CagriSema in Focus

One drug investors are watching closely is CagriSema, Novo’s next-generation weight-loss candidate. Doustdar said he expects it to be one of the company’s strongest launches next year.

However, expectations have been tempered. CagriSema delivered less weight loss than Eli Lilly’s Zepbound in a head-to-head trial earlier this year, putting pressure on how Novo positions the drug commercially.

On the capital side, Novo has continued its share buyback programme. Between 14 and 18 September 2026, the company purchased an additional 1.09 million B shares. Total repurchases since February now stand at 34.17 million B shares for DKK 9.63 billion, out of a planned DKK 15 billion programme.

The most recent analyst rating on NVO is a Hold with a $47.00 price target. The stock’s current market cap sits at approximately $191.7 billion.